Search results
Showing 61 to 75 of 205 results for lymphoma
Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
In development Reference number: GID-TA11545 Expected publication date: 11 February 2026
In development Reference number: GID-TA11298 Expected publication date: TBC
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.
In development Reference number: GID-TA11823 Expected publication date: TBC
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.
Find out which guidance and quality standards are awaiting development
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)
Evidence-based recommendations for the adjuvant treatment of ALK-positive non-small-cell lung cancer in adults.
Show all sections
high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which...
first-line treatment of diffuse large B-cell lymphoma:- In people presenting with diffuse large B-cell lymphoma and sites...
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
imaging for people with diffuse large B-cell lymphoma stage II or above:- In people with diffuse large B-cell lymphoma...
In development Reference number: GID-TA11230 Expected publication date: 07 May 2026
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1071)
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.